Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
This study is a single-arm, phase IV trial, of apixaban as treatment of venous thrombosis in
patients with cancer. The current standard treatment of venous thrombosis in cancer patients
is subcutaneous injections with low molecular weight heparin. During the last 5 years several
new direct acting oral anticoagulants have been tested out as treatment of venous thrombosis.
But very few cancer patients were included in the phase III clinical trials of the direct
acting oral anticoagulants. Thus, there is a lack of information on how cancer patients with
venous thrombosis will respond to treatment with direct acting oral anticoagulants. The
current study will investigate the direct acting oral anticoagulant apixaban in cancer
patients with venous thrombosis.